Wuhan YZY Biopharma Co., Ltd.

SEHK:2496 Stock Report

Market Cap: HK$754.1m

Wuhan YZY Biopharma Past Earnings Performance

Past criteria checks 0/6

Wuhan YZY Biopharma has been growing earnings at an average annual rate of 1.2%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 2.2% per year.

Key information

1.2%

Earnings growth rate

7.4%

EPS growth rate

Biotechs Industry Growth11.0%
Revenue growth rate2.2%
Return on equity-370.1%
Net Margin-2,275.4%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Is Wuhan YZY Biopharma (HKG:2496) Using Debt In A Risky Way?

Oct 02
Is Wuhan YZY Biopharma (HKG:2496) Using Debt In A Risky Way?

Revenue & Expenses Breakdown

How Wuhan YZY Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SEHK:2496 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 248-18427154
31 Mar 2410-18825154
31 Dec 2312-19222155
30 Sep 2310-18922151
30 Jun 238-18621147
31 Mar 235-18721152
31 Dec 222-18921157
31 Dec 2112-14931113

Quality Earnings: 2496 is currently unprofitable.

Growing Profit Margin: 2496 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 2496's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare 2496's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2496 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.1%).


Return on Equity

High ROE: 2496 has a negative Return on Equity (-370.1%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies